Market Closed -
Nasdaq
21:00:00 26/04/2024 BST
|
5-day change
|
1st Jan Change
|
156.9
USD
|
+0.77%
|
|
-1.04%
|
+26.45%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
958.5
|
1,182
|
1,742
|
2,040
|
3,499
|
4,473
|
-
|
-
|
Enterprise Value (EV)
1 |
774.3
|
918.1
|
1,304
|
1,661
|
2,905
|
3,910
|
3,734
|
3,388
|
P/E ratio
|
-46.2
x
|
-35.1
x
|
-22.3
x
|
-14.4
x
|
318
x
|
82.6
x
|
30.7
x
|
18.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
69
x
|
17.2
x
|
10.6
x
|
7.39
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
57.3
x
|
15
x
|
8.82
x
|
5.6
x
|
EV / EBITDA
|
-36.3
x
|
-29.5
x
|
-19.9
x
|
-11.5
x
|
-27.4
x
|
59
x
|
23.1
x
|
10.8
x
|
EV / FCF
|
-
|
-22.4
x
|
-11.2
x
|
-10.8
x
|
-28.9
x
|
36.7
x
|
16.2
x
|
10.1
x
|
FCF Yield
|
-
|
-4.46%
|
-8.92%
|
-9.25%
|
-3.46%
|
2.72%
|
6.15%
|
9.89%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
17,308
|
19,708
|
24,906
|
25,748
|
28,206
|
28,515
|
-
|
-
|
Reference price
2 |
55.38
|
60.00
|
69.95
|
79.22
|
124.1
|
156.9
|
156.9
|
156.9
|
Announcement Date
|
10/03/20
|
01/03/21
|
28/02/22
|
27/02/23
|
26/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
50.7
|
260
|
423.3
|
605.6
|
EBITDA
1 |
-21.33
|
-31.15
|
-65.51
|
-144.1
|
-106
|
66.31
|
161.4
|
312.9
|
EBIT
1 |
-22.08
|
-33
|
-68.28
|
-145.2
|
-109.7
|
43.65
|
165.6
|
307.6
|
Operating Margin
|
-
|
-
|
-
|
-
|
-216.43%
|
16.79%
|
39.11%
|
50.8%
|
Earnings before Tax (EBT)
1 |
-19.09
|
-32.17
|
-69.57
|
-140
|
12.9
|
65.31
|
196.8
|
334.5
|
Net income
1 |
-19.09
|
-32.17
|
-69.57
|
-140
|
10.93
|
46.06
|
146.1
|
264.2
|
Net margin
|
-
|
-
|
-
|
-
|
21.56%
|
17.71%
|
34.52%
|
43.63%
|
EPS
2 |
-1.200
|
-1.710
|
-3.130
|
-5.490
|
0.3900
|
1.899
|
5.114
|
8.537
|
Free Cash Flow
1 |
-
|
-40.93
|
-116.3
|
-153.5
|
-100.6
|
106.5
|
229.8
|
335
|
FCF margin
|
-
|
-
|
-
|
-
|
-198.43%
|
40.96%
|
54.3%
|
55.31%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
160.6%
|
142.39%
|
107.06%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
231.22%
|
157.3%
|
126.76%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/03/20
|
01/03/21
|
28/02/22
|
27/02/23
|
26/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
8.556
|
42.14
|
47.42
|
60.55
|
71.72
|
80.51
|
-
|
EBITDA
1 |
-
|
-21.09
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
4.298
|
18.25
|
33.83
|
45.59
|
51.52
|
-
|
EBIT
1 |
-15.65
|
-21.88
|
-25.22
|
-28.75
|
-31.45
|
-34.77
|
-48.82
|
-38.05
|
-25.99
|
3.138
|
1.506
|
9.099
|
19.54
|
21.11
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-303.8%
|
7.45%
|
3.18%
|
15.03%
|
27.24%
|
26.22%
|
-
|
Earnings before Tax (EBT)
1 |
-15.59
|
-21.81
|
-49.96
|
-28.11
|
-29.85
|
-32.05
|
-45.3
|
-33.21
|
80.75
|
10.66
|
4.744
|
15.25
|
22.3
|
25.64
|
-
|
Net income
1 |
-15.59
|
-21.81
|
-49.96
|
-28.11
|
-29.85
|
-32.05
|
-45.3
|
-33.21
|
80.75
|
8.692
|
4.086
|
12.4
|
18.02
|
20.45
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
943.75%
|
20.63%
|
8.62%
|
20.48%
|
25.12%
|
25.39%
|
-
|
EPS
2 |
-0.7000
|
-0.9500
|
-1.990
|
-1.100
|
-1.170
|
-1.250
|
-1.760
|
-1.250
|
2.790
|
0.3100
|
0.1457
|
0.3183
|
0.6314
|
0.6586
|
0.7200
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
08/11/21
|
28/02/22
|
09/05/22
|
08/08/22
|
07/11/22
|
27/02/23
|
08/05/23
|
07/08/23
|
06/11/23
|
26/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
184
|
264
|
438
|
379
|
594
|
564
|
739
|
1,085
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-40.9
|
-116
|
-154
|
-101
|
107
|
230
|
335
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-15.7%
|
-25.1%
|
-11.4%
|
13.1%
|
20.8%
|
19.1%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-
|
-
|
-2.160
|
-3.950
|
-3.200
|
2.810
|
3.890
|
-
|
Capex
1 |
-
|
14.8
|
68.3
|
0.05
|
11.8
|
8
|
10
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
23.27%
|
3.08%
|
2.36%
|
-
|
Announcement Date
|
10/03/20
|
01/03/21
|
28/02/22
|
27/02/23
|
26/02/24
|
-
|
-
|
-
|
Last Close Price
156.9
USD Average target price
188.5
USD Spread / Average Target +20.16% Consensus |
1st Jan change
|
Capi.
|
---|
| +26.45% | 4.47B | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|